Targeted Oncology View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

2006

PUBLISHER

Springer International Publishing

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/11523

Recent publications latest 20 shown

  • 2019-04-11 Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
  • 2019-04-03 Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis
  • 2019-03-30 Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
  • 2019-03-29 Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
  • 2019-03-29 Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy
  • 2019-03-23 Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
  • 2019-03-20 Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
  • 2019-03-19 Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
  • 2019-03-18 Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
  • 2019-03-04 Rucaparib: A Review in Ovarian Cancer
  • 2019-02-27 EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
  • 2019-02-26 Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
  • 2019-02-25 The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
  • 2019-02 Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy
  • 2019-02 Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
  • 2019-02 The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
  • 2019-02 Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
  • 2019-02 Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
  • 2019-02 BI 853520, a FAK-Simile of Prior FAK Inhibitors?
  • 2019-02 Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B0000X", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Biomedicine, general", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "0.798", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "1.304", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "3.907", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "3.438", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "3.197", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "4.000", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "3.458", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "0.455", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "2.764", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "0.455", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.614", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "2.054", 
            "type": "Rating"
          }
        ], 
        "description": "

    Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.

    Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.

    Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

    Targeted Oncology offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal\u2019s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager\u00ae, supported by a database of international experts. This database is shared with other Adis journals.

    All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

    ", "editor": [ { "familyName": "Chopra", "givenName": "Martin", "type": "Person" } ], "id": "sg:journal.1036678", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "1776-2596", "1776-260X" ], "license": "Hybrid (Open Choice)", "name": "Targeted Oncology", "productId": [ { "name": "scopus_id", "type": "PropertyValue", "value": [ "4700152489" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "1776-2596/TARGETED ONCOLOGY" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "101270595" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "481133" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "11523" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "2006243434" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "36678" ] } ], "publisher": { "name": "Springer International Publishing", "type": "Organization" }, "publisherImprint": "Adis", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1036678" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "2006", "type": "Periodical", "url": "http://link.springer.com/journal/11523" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1036678'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1036678'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1036678'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1036678'


     

    This table displays all metadata directly associated to this object as RDF triples.

    146 TRIPLES      21 PREDICATES      41 URIs      35 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1036678 schema:about sg:ontologies/product-market-codes/B0000X
    2 sg:ontologies/product-market-codes/H33160
    3 schema:contentRating N01821dc7685943d6b1a49d77b324efeb
    4 N0f4b3cdd94764ec3a6ba352099bc4386
    5 N1653fa59799748d1bd282160ef28caeb
    6 N569bd694c7b247a186303263a2f91914
    7 N59c28216d4ba47ffac9406623bccf700
    8 N6b9cfeea283d4a3db7ea2cd37ebb38f6
    9 N6b9ea891fcf04f7fa9a330d58463c5f4
    10 Na4a72544ea494dcf8111c3d79403e2a8
    11 Nbf0fffbc51f54172add8bcf8175999aa
    12 Nd0b64fd16a4f47fea2eb0fd19da69dde
    13 Nf4438a267d4a48de92c52d01d14b8ef0
    14 Nf8bb6e89f84a48b88b6f6fb2003dc7e2
    15 schema:description <p><i>Targeted Oncology</i> is a pragmatic tool for all physicians and scientists committed to oncology and cancer research. </p><p>Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.</p><p><i>Targeted Oncology</i> focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.</p><p><i>Targeted Oncology</i> offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.</p><p>All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.</p>
    16 schema:editor N00db44d45644491e9fbf8bd077b07e5a
    17 schema:inLanguage en
    18 schema:isAccessibleForFree false
    19 schema:issn 1776-2596
    20 1776-260X
    21 schema:license Hybrid (Open Choice)
    22 schema:name Targeted Oncology
    23 schema:productId N22800f706bee4b4096c1e34f090b3271
    24 N55ac9a1587a14700bb0d9b1dd4752ccc
    25 N63decb58ae9e4fff97650ef435297a4b
    26 N9edb757fb3114f8d8aa0e0ffa69e7844
    27 Na502f5951dfa416e9c2a48ccad554a00
    28 Nac25d55c5aa14c2885d653f1dd4fe098
    29 Nd7bb90ee185d4106a951df6ff147db19
    30 schema:publisher Nebe18e8bda3b4688bad0b6bae36fd789
    31 schema:publisherImprint Adis
    32 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1036678
    33 schema:sdDatePublished 2019-03-18T11:05
    34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    35 schema:sdPublisher N00bc4ddf6f4b495a81692155655c5c71
    36 schema:startYear 2006
    37 schema:url http://link.springer.com/journal/11523
    38 sgo:license sg:explorer/license/
    39 sgo:sdDataset journals
    40 rdf:type schema:Periodical
    41 N00bc4ddf6f4b495a81692155655c5c71 schema:name Springer Nature - SN SciGraph project
    42 rdf:type schema:Organization
    43 N00db44d45644491e9fbf8bd077b07e5a rdf:first N174da4eb389c4839b1a5e755907f5000
    44 rdf:rest rdf:nil
    45 N01821dc7685943d6b1a49d77b324efeb schema:author N2b7d0795ddf94b188b475a2e89e83974
    46 schema:dateCreated 2011
    47 schema:ratingValue 3.614
    48 rdf:type schema:Rating
    49 N0564855ccce5449c86348311723118a2 rdf:first impact_factor_wos
    50 rdf:rest rdf:nil
    51 N0f4b3cdd94764ec3a6ba352099bc4386 schema:author Nba3d10673ce54c908af4e7fb3f513967
    52 schema:dateCreated 2010
    53 schema:ratingValue 2.054
    54 rdf:type schema:Rating
    55 N1653fa59799748d1bd282160ef28caeb schema:author N6c96c755be20444cb8de27dae8a61a55
    56 schema:ratingValue 1.304
    57 rdf:type schema:Rating
    58 N174da4eb389c4839b1a5e755907f5000 schema:familyName Chopra
    59 schema:givenName Martin
    60 rdf:type schema:Person
    61 N22800f706bee4b4096c1e34f090b3271 schema:name lccn_id
    62 schema:value 2006243434
    63 rdf:type schema:PropertyValue
    64 N2b7d0795ddf94b188b475a2e89e83974 rdf:first impact_factor_wos
    65 rdf:rest rdf:nil
    66 N2d1702eeca134edba8f26c11e72ab362 rdf:first impact_factor_wos
    67 rdf:rest rdf:nil
    68 N432e1b2e22504990b7aef0663264c4ad rdf:first impact_factor_wos
    69 rdf:rest rdf:nil
    70 N55ac9a1587a14700bb0d9b1dd4752ccc schema:name nsd_ids_id
    71 schema:value 481133
    72 rdf:type schema:PropertyValue
    73 N569bd694c7b247a186303263a2f91914 schema:author N432e1b2e22504990b7aef0663264c4ad
    74 schema:dateCreated 2009
    75 schema:ratingValue 0.455
    76 rdf:type schema:Rating
    77 N59c28216d4ba47ffac9406623bccf700 schema:author Nc921b84ef87d4a0b9a885a551dacd1e6
    78 schema:dateCreated 2014
    79 schema:ratingValue 4.000
    80 rdf:type schema:Rating
    81 N63decb58ae9e4fff97650ef435297a4b schema:name scopus_id
    82 schema:value 4700152489
    83 rdf:type schema:PropertyValue
    84 N6b9cfeea283d4a3db7ea2cd37ebb38f6 schema:author Nde7e2bec24b347fa9be58eb8d7af5501
    85 schema:dateCreated 2013
    86 schema:ratingValue 3.458
    87 rdf:type schema:Rating
    88 N6b9ea891fcf04f7fa9a330d58463c5f4 schema:author N0564855ccce5449c86348311723118a2
    89 schema:dateCreated 2012
    90 schema:ratingValue 2.764
    91 rdf:type schema:Rating
    92 N6c96c755be20444cb8de27dae8a61a55 rdf:first sjr
    93 rdf:rest rdf:nil
    94 N9edb757fb3114f8d8aa0e0ffa69e7844 schema:name springer_id
    95 schema:value 11523
    96 rdf:type schema:PropertyValue
    97 Na4a72544ea494dcf8111c3d79403e2a8 schema:author Nece44735b7a24e49bc23abd901a0b712
    98 schema:dateCreated 2009
    99 schema:ratingValue 0.455
    100 rdf:type schema:Rating
    101 Na502f5951dfa416e9c2a48ccad554a00 schema:name nlm_unique_id
    102 schema:value 101270595
    103 rdf:type schema:PropertyValue
    104 Nac25d55c5aa14c2885d653f1dd4fe098 schema:name wos_id
    105 schema:value 1776-2596/TARGETED ONCOLOGY
    106 rdf:type schema:PropertyValue
    107 Nba3d10673ce54c908af4e7fb3f513967 rdf:first impact_factor_wos
    108 rdf:rest rdf:nil
    109 Nbed161413d234ac0b3b01447aa712b9d rdf:first impact_factor_wos
    110 rdf:rest rdf:nil
    111 Nbf0fffbc51f54172add8bcf8175999aa schema:author Nbed161413d234ac0b3b01447aa712b9d
    112 schema:dateCreated 2016
    113 schema:ratingValue 3.438
    114 rdf:type schema:Rating
    115 Nc921b84ef87d4a0b9a885a551dacd1e6 rdf:first impact_factor_wos
    116 rdf:rest rdf:nil
    117 Nca889f1e69d44620a167132ace6d2dc7 rdf:first impact_factor_wos
    118 rdf:rest rdf:nil
    119 Nd0b64fd16a4f47fea2eb0fd19da69dde schema:author Nd903f85d3d0249c8a3770e5482ffa386
    120 schema:ratingValue 0.798
    121 rdf:type schema:Rating
    122 Nd7bb90ee185d4106a951df6ff147db19 schema:name dimensions_id
    123 schema:value 36678
    124 rdf:type schema:PropertyValue
    125 Nd903f85d3d0249c8a3770e5482ffa386 rdf:first snip
    126 rdf:rest rdf:nil
    127 Nde7e2bec24b347fa9be58eb8d7af5501 rdf:first impact_factor_wos
    128 rdf:rest rdf:nil
    129 Nebe18e8bda3b4688bad0b6bae36fd789 schema:name Springer International Publishing
    130 rdf:type schema:Organization
    131 Nece44735b7a24e49bc23abd901a0b712 rdf:first impact_factor_wos
    132 rdf:rest rdf:nil
    133 Nf4438a267d4a48de92c52d01d14b8ef0 schema:author Nca889f1e69d44620a167132ace6d2dc7
    134 schema:dateCreated 2015
    135 schema:ratingValue 3.197
    136 rdf:type schema:Rating
    137 Nf8bb6e89f84a48b88b6f6fb2003dc7e2 schema:author N2d1702eeca134edba8f26c11e72ab362
    138 schema:dateCreated 2017
    139 schema:ratingValue 3.907
    140 rdf:type schema:Rating
    141 sg:ontologies/product-market-codes/B0000X schema:inDefinedTermSet sg:ontologies/product-market-codes/
    142 schema:name Biomedicine, general
    143 rdf:type schema:DefinedTerm
    144 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    145 schema:name Oncology
    146 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...